Erythroid cell patterns in neoplasms show distinct genomic profile and poor venetoclax response, new research suggests.

Schrödinger is discontinuing the development of its blood cancer CDC7 inhibitor after two patient deaths. In a Phase I trial ...

Few patients with MDS receive treatment with hypomethylating agents, with evidence of age-, sex-, and race-related disparities.

New long-term data from the COMMANDS trial reveals that luspatercept significantly prolongs survival for patients with low-risk MDS.

Manero, MD, discusses findings from the phase 3 COMMANDS trial evaluating luspatercept in patients with myelodysplastic ...

Researchers sought to determine whether elderly, fit patients with AML would respond to therapy with venetoclax plus modified intensive chemotherapy.

A new market analysis projects the global myelodysplastic syndrome (MDS) treatment market will grow from an estimated value ...